MNPR

MNPR

USD

Monopar Therapeutics Inc. Common Stock

$82.710-3.240 (-3.770%)

Precio en Tiempo Real

Healthcare
Biotecnología
Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$85.950

Máximo

$86.140

Mínimo

$80.105

Volumen

0.14M

Fundamentos de la Empresa

Capitalización de Mercado

510.3M

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

0.07M

Bolsa

NCM

Moneda

USD

Rango de 52 Semanas

Mínimo $14.877Actual $82.710Máximo $105

Noticias Relacionadas

Analyst Upgrades

Barclays Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target of $125

Barclays analyst Etzer Darout initiates coverage on Monopar Therapeutics with a Overweight rating and announces Price Target of $125.

Ver más
Barclays Initiates Coverage On Monopar Therapeutics with Overweight Rating, Announces Price Target of $125
Analyst Upgrades

Raymond James Maintains Strong Buy on Monopar Therapeutics, Raises Price Target to $142

Raymond James analyst Chris Raymond maintains Monopar Therapeutics with a Strong Buy and raises the price target from $80 to $142.

Ver más
Raymond James Maintains Strong Buy on Monopar Therapeutics, Raises Price Target to $142
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $105

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Monopar Therapeutics with a Buy and raises the price target from $70 to $105.

Ver más
HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $105
Analyst Upgrades

Piper Sandler Maintains Overweight on Monopar Therapeutics, Raises Price Target to $95

Piper Sandler analyst Biren Amin maintains Monopar Therapeutics with a Overweight and raises the price target from $76 to $95.

Ver más
Piper Sandler Maintains Overweight on Monopar Therapeutics, Raises Price Target to $95
Analyst Upgrades

Chardan Capital Maintains Buy on Monopar Therapeutics, Raises Price Target to $85

Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics with a Buy and raises the price target from $60 to $85.

Ver más
Chardan Capital Maintains Buy on Monopar Therapeutics, Raises Price Target to $85
Analyst Upgrades

BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $104

BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics with a Buy and raises the price target from $87 to $104.

GlobeNewswire

Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar Therapeutics", "Monopar", or the "Company"), a clinical-stage biopharmaceutical company developing innovative

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.